{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:16:37Z","timestamp":1791497797485,"version":"4.3.4"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"vor","delay-in-days":50,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Patients with Crohn\u2019s disease (CD) or ulcerative colitis (UC) often cycle through conventional therapies (CT) with different mechanisms of action (MOA) before initiating advanced therapy (AT). We describe treatment patterns among patients with CD\/UC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Using Merative MarketScan Research databases, adult patients with CD\/UC were identified from medical\/pharmacy claims (2017\u20132021). Patients had \u22651 hospitalization or \u22652 outpatient visits (\u226530 days apart within 1 year) for CD\/UC. Two cohorts were established; cohort 1: Newly diagnosed patients (index date is the date of first diagnosis) and cohort 2: Patients initiating AT (index date is the date of first AT). First-line treatment patterns (cohort 1) and CT pathways before AT initiation (cohort 2) by the number of episodes (ie, adding a new therapy, switching to another therapy, or restarting the same therapy after \u226560 days) and MOA are reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among newly diagnosed patients in cohort 1 (CD: n\u2005=\u20051739; UC: n\u2005=\u20052740), 14.4% (CD) and 5.9% (UC) of patients had any AT use during the follow-up period (mean: 2.3 years;\u2005\u2265\u200577% initiated corticosteroids). Among patients in cohort 2 (CD: n\u2005=\u20052594; UC: n\u2005=\u20052431), the mean number of CT episodes before AT initiation was 4.0\u2005\u00b1\u20054.3 (CD) and 5.9\u2005\u00b1\u20055.0 (UC). Among those with \u22651 corticosteroid episode (CD: 82.2%; UC: 91.5%), the mean number of episodes was 4.6\u2005\u00b1\u20054.3 (CD) and 6.3\u2005\u00b1\u20055.0 (UC). Overall, 13.3% (CD) and 23.7% (UC) of patients cycled through 3 MOAs before AT initiation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Despite treatment recommendations, few newly diagnosed CD\/UC patients initiated AT as their first treatment. Moreover, patients cycled through multiple CTs before initiating AT.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/crocol\/otae040","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T14:39:57Z","timestamp":1724164797000},"source":"Crossref","is-referenced-by-count":20,"title":["Treatment Pathways in Patients With Crohn\u2019s Disease and Ulcerative Colitis: Understanding the Road to Advanced Therapy"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2240-6605","authenticated-orcid":false,"given":"Corey A","family":"Siegel","sequence":"first","affiliation":[{"name":"Inflammatory Bowel Disease Center, Section of Gastroenterology and Hepatology, Dartmouth Hitchcock Medical Center , Lebanon, NH , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolly","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Health Economics and Outcomes Research,\u00a0AbbVie, Inc , North\u00a0Chicago, IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Griffith","sequence":"additional","affiliation":[{"name":"Department of Health Economics and Outcomes Research,\u00a0AbbVie, Inc , North\u00a0Chicago, IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quynhchau","family":"Doan","sequence":"additional","affiliation":[{"name":"Department of Health Economics and Outcomes Research,\u00a0AbbVie, Inc , North\u00a0Chicago, IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si","family":"Xuan","sequence":"additional","affiliation":[{"name":"Department of Health Economics and Outcomes Research,\u00a0AbbVie, Inc , North\u00a0Chicago, IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Malter","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, New York University Langone Medical Center , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,20]]},"reference":[{"issue":"2","key":"2024082906233053900_CIT0001","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/apt.13255","article-title":"Assessing fatigue in inflammatory bowel disease: comparison of three fatigue scales","volume":"42","author":"Norton","year":"2015","journal-title":"Aliment Pharmacol Ther."},{"issue":"1","key":"2024082906233053900_CIT0002","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/apt.16145","article-title":"Fatigue in inflammatory bowel disease and its impact on daily activities","volume":"53","author":"Schreiner","year":"2021","journal-title":"Aliment Pharmacol Ther."},{"issue":"4","key":"2024082906233053900_CIT0003","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/ibd\/izx100","article-title":"Quality of life in inflammatory bowel disease: a systematic review and meta-analyses-Part I","volume":"24","author":"Knowles","year":"2018","journal-title":"Inflamm Bowel Dis."},{"issue":"5","key":"2024082906233053900_CIT0004","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/ibd\/izy015","article-title":"Quality of life in inflammatory bowel disease: a systematic review and meta-analyses-Part II","volume":"24","author":"Knowles","year":"2018","journal-title":"Inflamm Bowel Dis."},{"key":"2024082906233053900_CIT0005","article-title":"Health Care Utilization Among U.S. Adults With Inflammatory Bowel Disease, 2015\u20132016","author":"Terlizzi","year":"2021"},{"issue":"4","key":"2024082906233053900_CIT0006","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s00384-021-03876-z","article-title":"Long-term cost and complications of surgery in patients with ulcerative colitis: a claims data analysis","volume":"36","author":"Ghiani","year":"2021","journal-title":"Int J Colorectal Dis."},{"key":"2024082906233053900_CIT0007","first-page":"S51","article-title":"Economic implications of inflammatory bowel disease and its management","volume":"22","author":"Mehta","year":"2016","journal-title":"Am J Manag Care."},{"issue":"6","key":"2024082906233053900_CIT0008","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00535-021-01784-1","article-title":"Evidence-based clinical practice guidelines for inflammatory bowel disease 2020","volume":"56","author":"Nakase","year":"2021","journal-title":"J Gastroenterol."},{"issue":"5","key":"2024082906233053900_CIT0009","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology."},{"issue":"8","key":"2024082906233053900_CIT0010","first-page":"e16859","article-title":"A review of four practice guidelines of inflammatory bowel disease","volume":"13","author":"Okobi","year":"2021","journal-title":"Cureus"},{"issue":"9613","key":"2024082906233053900_CIT0011","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","article-title":"Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn\u2019s disease: an open randomised trial","volume":"371","author":"D\u2019Haens","year":"2008","journal-title":"Lancet."},{"issue":"5","key":"2024082906233053900_CIT0012","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S2468-1253(24)00034-7","article-title":"A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn\u2019s disease (PROFILE): a multicentre, open-label randomised controlled trial","volume":"9","author":"Noor","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"2024082906233053900_CIT0013","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/ibd\/izad149","article-title":"Early biologic treatment decreases risk of surgery in Crohn\u2019s disease but not in ulcerative colitis: systematic review and meta-analysis","volume":"30","author":"Law","year":"2023","journal-title":"Inflamm Bowel Dis."},{"issue":"2","key":"2024082906233053900_CIT0014","doi-asserted-by":"crossref","first-page":"e00128","DOI":"10.14309\/ctg.0000000000000128","article-title":"Treatment pathways leading to biologic therapies for ulcerative colitis and Crohn\u2019s disease in the United States","volume":"11","author":"Siegel","year":"2020","journal-title":"Clin Transl Gastroenterol"},{"issue":"7","key":"2024082906233053900_CIT0015","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","article-title":"AGA Clinical Practice Guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn\u2019s Disease","volume":"160","author":"Feuerstein","year":"2021","journal-title":"Gastroenterology."},{"issue":"5","key":"2024082906233053900_CIT0016","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA Clinical Practice Guidelines on the management of moderate to severe ulcerative colitis","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology."},{"issue":"3","key":"2024082906233053900_CIT0017","doi-asserted-by":"crossref","first-page":"otac021","DOI":"10.1093\/crocol\/otac021","article-title":"Indicators of suboptimal treatment and associated healthcare costs among patients with Crohn\u2019s Disease initiated on biologic or conventional agents","volume":"4","author":"Pilon","year":"2022","journal-title":"Crohns Colitis 360."},{"issue":"15","key":"2024082906233053900_CIT0018","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.3390\/jcm11154586","article-title":"Machine learning can predict the probability of biologic therapy in patients with Inflammatory Bowel Disease","volume":"11","author":"Scholer","year":"2022","journal-title":"J Clin Med"},{"issue":"9","key":"2024082906233053900_CIT0019","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/ibd\/izaa032","article-title":"Identifying IBD providers\u2019 knowledge gaps using a Prospective Web-based Survey","volume":"26","author":"Malter","year":"2020","journal-title":"Inflamm Bowel Dis."},{"issue":"2","key":"2024082906233053900_CIT0020","doi-asserted-by":"crossref","first-page":"e21639","DOI":"10.2196\/21639","article-title":"Developing patient-centered inflammatory bowel disease-related educational videos optimized for social media: qualitative research study","volume":"6","author":"Khalil","year":"2020","journal-title":"JMIR Med Educ"},{"issue":"10","key":"2024082906233053900_CIT0021","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/apa.15211","article-title":"Knowledge of disease and self-management of adolescents with inflammatory bowel diseases","volume":"109","author":"Krauthammer","year":"2020","journal-title":"Acta Paediatr."}],"container-title":["Crohn's &amp; Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otae040\/58864740\/otae040.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otae040\/58958389\/otae040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otae040\/58958389\/otae040.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T06:27:46Z","timestamp":1724912866000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article\/doi\/10.1093\/crocol\/otae040\/7736963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/crocol\/otae040","relation":{},"ISSN":["2631-827X"],"issn-type":[{"value":"2631-827X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,7,1]]},"article-number":"otae040"}}